Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Top 10 Correlated ETFs
In the News
GSK board appointment is positive says broker but focus is on weak GBP, Zantac legals
The rise in GSK PLC (LSE:GSK, NYSE:GSK) shares on the reporting of a finance chief was probably more to do with the slide in sterling, than the market's excitement about the creation of an all-female top team, said Barclays. Following the drug maker announcing that Julie Brown is being poached from Burberry to take the role of chief financial officer as Iain Mackay retires, the general reception to the news today has been positive, the bank said.
AstraZeneca, BAT, Ferguson, 4imprint and other exporters get double-benefit from sterling crash
As the pound crashed following Kwasi Kwarteng's quasi-infamous ‘mini' budget, many crafty currency speculators made a quick fortune, while savvy stock market investors are still mulling which companies are likely to benefit most. Sterling has never been so weak, which in theory should make products sold by UK exporters potentially very much more attractive.
GSK poaches Burberry CFO to complete rare all-female executive leadership team
GSK PLC (LSE:GSK, NYSE:GSK) poached Burberry Group PLC (LSE:BRBY)'s chief financial officer (CFO) Julie Brown to complete a rare but all-female executive leadership team. Brown will replace Iain Mackay, who has been finance chief at the FTSE-100 pharmaceuticals giant since 2019.
GSK picks Burberry's Brown as first female CFO
GSK named luxury fashion brand Burberry's Julie Brown as its first ever female chief financial officer on Monday to succeed Iain Mackay, at a time when the British drugmaker is sharpening focus on its core business.
GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News
British drugmaker GSK plc , has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday.
7 Stocks to Buy That Can Soar in Good Times or in Bad
Many commentators, analysts, and economists are convinced that the U.S. will enter a recession next year. Given the strength of the labor market and of corporate balance sheets, along with the onshoring phenomenon and the many jobs that the energy transition is creating, I have my doubts as to whether a recession is on the way.
Spero's stock jumps 188% after GSK licenses experimental antibiotic
Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year.
GSK to shell out an initial US$75mln to gain rights to a next-generation antibiotic
GSK PLC (LSE:GSK, NYSE:GSK) has inked a licensing deal with a Cambridge, Massachusetts, biotech that will give it access to an oral antibiotic for complicated urinary tract infections. The UK group is paying Spero Therapeutics Inc an initial US$66mln to licence the latter's tebipenem pivoxil hydrobromide, which is about to enter phase III clinical trials.
Is Trending Stock GSK PLC Sponsored ADR (GSK) a Buy Now?
Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 Dividend Stocks to Double Up On Right Now
These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
|Revenue per share||15.45||15.68||17.06||17.13||17.05|
|Net income per share||0.78||1.84||2.35||2.89||2.19|
|Operating cash flow per share||3.54||4.28||4.05||4.24||3.97|
|Free cash flow per share||2.41||3.37||2.96||3.12||2.51|
|Cash per share||2||2.01||2.42||3.1||2.07|
|Book value per share||-0.03||2.22||5.76||7.33||7.52|
|Tangible book value per share||-10.13||-9.83||-11.7||-9.85||-9.64|
|Share holders equity per share||-0.03||2.22||5.76||7.33||7.52|
|Interest debt per share||9.12||13.65||15.86||14.07||12.47|
|Price to sales ratio||1.84||1.84||2.05||1.62||1.98|
|EV to sales||2.28||2.56||2.81||2.24||2.56|
|Enterprise value over EBITDA||12.39||11.25||10.77||8||11.1|
|EV to operating cash flow||9.93||9.36||11.84||9.03||11|
|EV to free cash flow||14.57||11.9||16.22||12.29||17.43|
|Free cash flow yield||0.09||0.12||0.08||0.11||0.07|
|Debt to equity||-209.76||4.65||2.07||1.61||1.37|
|Debt to assets||0.94||0.94||0.77||0.74||0.73|
|Net debt to EBITDA||2.39||3.17||2.93||2.21||2.55|
|Sales general and administrative to revenue||0.32||0.32||0.34||0.34||0.32|
|Research and developement to revenue||0.15||0.13||0.14||0.15||0.15|
|Intangibles to total assets||0.41||0.4||0.52||0.5||0.51|
|Capex to operating cash flow||-0.32||-0.21||-0.27||-0.27||-0.37|
|Capex to revenue||-0.07||-0.06||-0.06||-0.07||-0.09|
|Capex to depreciation||-1.15||-0.97||-0.93||-0.95||-1.23|
|Stock based compensation to revenue||0.01||0.01||0.01||0.01||0.01|
|Return on tangible assets||0.05||0.1||0.12||0.14||0.11|
|Tangible asset value||-19.81B||-19.32B||-23.16B||-19.61B||-19.29B|
|Net current asset value||-36.99B||-37.47B||-41.84B||-39.38B||-39.09B|
|Days sales outstanding||0||0||0||0||0|
|Days payables outstanding||124.51||129.91||127.5||135.88||142.66|
|Days of inventory on hand||196.12||195.17||182.98||186.99||181.92|
|Capex per share||-1.13||-0.91||-1.09||-1.12||-1.46|
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
|Revenue per share||4.04||4.53||4.74||4.87||4.3|
|Net income per share||0.7||0.58||0.37||0.9||0.52|
|Operating cash flow per share||0.65||1.28||1.88||1.27||1.02|
|Free cash flow per share||0.32||0.64||1.56||0.97||0.75|
|Cash per share||1.78||1.75||2.06||6.96||4.06|
|Book value per share||7.68||7.7||7.5||8.06||10.17|
|Tangible book value per share||-9.09||-9.52||-9.61||-9.23||3.33|
|Share holders equity per share||7.68||7.7||7.5||8.06||10.17|
|Interest debt per share||12.83||12.88||12.13||16.7||13.86|
|Price to sales ratio||7.33||6.28||6.92||6.66||7.53|
|EV to sales||10.05||8.72||9.03||8.94||9.79|
|Enterprise value over EBITDA||37.24||28.94||80.01||27.77||37.2|
|EV to operating cash flow||62.93||30.88||22.83||34.41||41.47|
|EV to free cash flow||128.85||61.9||27.43||45.06||56.09|
|Free cash flow yield||0.01||0.02||0.05||0.03||0.02|
|Debt to equity||1.33||1.34||1.37||1.81||1.15|
|Debt to assets||0.72||0.72||0.73||0.75||0.75|
|Net debt to EBITDA||10.07||8.1||18.7||7.1||8.58|
|Sales general and administrative to revenue||0.33||0.29||0.34||0.29||0.3|
|Research and developement to revenue||0.15||0.16||0.15||0.12||0.18|
|Intangibles to total assets||0.52||0.52||0.51||0.46||0.19|
|Capex to operating cash flow||-0.51||-0.5||-0.17||-0.24||-0.26|
|Capex to revenue||-0.08||-0.14||-0.07||-0.06||-0.06|
|Capex to depreciation||-1||-1.3||-1.73||-0.85||-0.68|
|Stock based compensation to revenue||0||0||0||0||0|
|Return on tangible assets||0.04||0.03||0.02||0.04||0.01|
|Tangible asset value||-18.19B||-19.08B||-19.29B||-18.54B||5.36B|
|Net current asset value||-37.87B||-38.69B||-39.09B||-38.07B||-12.22B|
|Days sales outstanding||0||0||0||0||0|
|Days payables outstanding||502.75||474.45||110.91||428.71||612.38|
|Days of inventory on hand||223.06||194.52||141.43||146.41||192.9|
|Capex per share||-0.33||-0.64||-0.31||-0.3||-0.26|
Frequently Asked Questions
What is GlaxoSmithKline plc stock symbol ?
GlaxoSmithKline plc is a GB stock and trading under the symbol GSK
What is GlaxoSmithKline plc stock quote today ?
GlaxoSmithKline plc stock price is $30.345 today.
Is GlaxoSmithKline plc stock public?
Yes, GlaxoSmithKline plc is a publicly traded company.